CNTB Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Connect Biopharma Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.02 |
| 52 Week High | US$2.66 |
| 52 Week Low | US$0.90 |
| Beta | -0.44 |
| 1 Month Change | 1.25% |
| 3 Month Change | -16.39% |
| 1 Year Change | -19.05% |
| 3 Year Change | -76.55% |
| 5 Year Change | n/a |
| Change since IPO | -94.48% |
Recent News & Updates
Connect Biopharma Holdings (NASDAQ:CNTB) Is In A Strong Position To Grow Its Business
Sep 27
Companies Like Connect Biopharma Holdings (NASDAQ:CNTB) Are In A Position To Invest In Growth
Mar 07Recent updates
Connect Biopharma Holdings (NASDAQ:CNTB) Is In A Strong Position To Grow Its Business
Sep 27Companies Like Connect Biopharma Holdings (NASDAQ:CNTB) Are In A Position To Invest In Growth
Mar 07Is Connect Biopharma Holdings (NASDAQ:CNTB) In A Good Position To Invest In Growth?
Sep 19Will Connect Biopharma Holdings (NASDAQ:CNTB) Spend Its Cash Wisely?
Mar 29Is Connect Biopharma Holdings (NASDAQ:CNTB) In A Good Position To Deliver On Growth Plans?
Dec 14Market Appears To Relegate Connect Biopharma To A Long-Term Hold
Oct 10Connect Biopharma Is A Sleeper Heading Into October Data Readout
Sep 26Connect Biopharma reports 1H results
Sep 13We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate
Aug 12We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate
Apr 29Connect Biopharma's Latest Dermatitis Drug Update Fails To Pump Up Shares
Jan 12We're Hopeful That Connect Biopharma Holdings (NASDAQ:CNTB) Will Use Its Cash Wisely
Jan 01Shareholder Returns
| CNTB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.9% | 2.0% | 2.4% |
| 1Y | -19.0% | -4.1% | 25.0% |
Return vs Industry: CNTB underperformed the US Biotechs industry which returned -6.1% over the past year.
Return vs Market: CNTB underperformed the US Market which returned 24.4% over the past year.
Price Volatility
| CNTB volatility | |
|---|---|
| CNTB Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.7% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: CNTB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CNTB's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 81 | Barry Quart | www.connectbiopharm.com |
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn’s disease.
Connect Biopharma Holdings Limited Fundamentals Summary
| CNTB fundamental statistics | |
|---|---|
| Market cap | US$58.02m |
| Earnings (TTM) | -US$21.38m |
| Revenue (TTM) | US$24.12m |
2.3x
P/S Ratio-2.6x
P/E RatioIs CNTB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CNTB income statement (TTM) | |
|---|---|
| Revenue | US$24.12m |
| Cost of Revenue | US$0 |
| Gross Profit | US$24.12m |
| Other Expenses | US$45.50m |
| Earnings | -US$21.38m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 100.00% |
| Net Profit Margin | -88.65% |
| Debt/Equity Ratio | 0% |
How did CNTB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/22 09:29 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Connect Biopharma Holdings Limited is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Louise Chen | Cantor Fitzgerald & Co. |
| Ziyu He | China International Capital Corporation Limited |
| Emily Bodnar | H.C. Wainwright & Co. |